Phase 1 Study OF CDC-501 in Patients With Solid Tumors

Summary

To identify the maximum tolerated dose (MTD) and safety of CDC-501 when given in a 6-week cycle in patients with solid tumors that are refractory after standard treatment.

Timeline

Start

2002-06-01

Primary completion

2006-08-01

Completion

2006-09-28

Publications

• Background Miller AA, Case D, Harmon M, Savage P, Lesser G, Hurd D, Melin SA. Phase I study of lenalidomide in solid tumors. J Thorac Oncol. 2007 May;2(5):445-9. doi: 10.1097/01.JTO.0000268679.33238.67.

Drugs

Indications